专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

CA2525917A1 COMPOSITIONS AND METHODS INCLUDING A RECOMBINANT HUMAN MAB THAT PROMOTES CNS REMYELINATION 未知
公开(公告)号：CA2525917A1
公开(公告)日：2004-12-23
申请号：CA2525917
申请日：2004-05-17
申请人： ACORDA THERAPEUTICS , MAYO FOUNDATION
发明人： RODRIGUEZ MOSES , WARRINGTON ARTHUR E , GRUSKIN ELLIOT A , BIEBER ALLAN J , CHOJNICKI ERIC
IPC分类号： A61K39/395 , A61K20060101 , A61K31/573 , A61P25/28 , C07K16/18
摘要： Antibodies, and particularly human antibodies, are disclosed that demonstrat e activity in the treatment of demyelinating diseases as well as other disease s of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapte n, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animais, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeuti c applications, and to pharmaceutical compositions containing them, that may b e administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.

2. 发明专利

ES2451993T3 Dosis bajas de anticuerpos IgM para tratamiento de trastornos desmielinizantes 未知
公开(公告)号：ES2451993T3
公开(公告)日：2014-03-28
申请号：ES04752450
申请日：2004-05-17
申请人： MAYO FOUNDATION , ACORDA THERAPEUTICS
发明人： GRUSKIN ELLIOT A , CHOJNICKI ERIC , WARRINGTON ARTHUR E , BIEBER ALLAN J , RODRIGUEZ MOSES
IPC分类号： A61K39/395 , A61K20060101 , A61K31/573 , C07K16/18
摘要： Una composición farmacéutica que comprende un anticuerpo IgM monoclonal humano, donde dicho anticuerpocomprende una secuencia de aminoácido de región variable de cadena pesada como se expone en la FIGURA 5 ySEQ ID NO: 7 y una secuencia de aminoácido de región variable de cadena ligera como se expone en la FIGURA 6y SEQ ID NO: 9, y un transportador, vehículo o diluyente farmacéuticamente aceptable, donde dicha composición espara su uso en el tratamiento o prevención de una enfermedad de desmielinización en un humano caracterizado enque el tratamiento o prevención comprende la administración del anticuerpo en una dosis diaria en el rango de 1,25μg/kg a 2,5 μg/kg de peso corporal.

3. 发明专利

CA2967294C COMPOSITIONS AND METHODS INCLUDING A RECOMBINANT HUMAN MAB THAT PROMOTES CNS REMYELINATION 未知
公开(公告)号：CA2967294C
公开(公告)日：2020-04-28
申请号：CA2967294
申请日：2004-05-17
申请人： MAYO FOUNDATION FOR MEDICAL EDUCATION & RES , ACORDA THERAPEUTICS INC
发明人： GRUSKIN ELLIOT A , CHOJNICKI ERIC , WARRINGTON ARTHUR E , BIEBER ALLAN J , RODRIGUEZ MOSES
IPC分类号： A61K51/10 , A61K20060101 , A61K31/573 , A61K49/16 , C07K16/18
摘要： Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animais, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.

4. 发明专利

AU2010202111B2 Compositions and methods including a recombinant human MAB that promotes CNS remyelination 未知
公开(公告)号：AU2010202111B2
公开(公告)日：2012-11-15
申请号：AU2010202111
申请日：2010-05-25
申请人： ACORDA THERAPEUTICS , MAYO FOUNDATION FOR MEDICAL EDUCATION & RES
发明人： RODRIGUEZ MOSES , GRUSKIN ELLIOT A , CHOJNICKI ERIC , WARRINGTON ARTHUR E , BIEBER ALLAN J
IPC分类号： C07K16/18 , A61K20060101 , A61K31/573 , A61K39/395
摘要： Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, 5 bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the 0 central nervous system of humans and domestic animais, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHlgM MSI I 9D 10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSII9E5 and MSII0El 0, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical 5 compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination. -CJ 4') c 0 _____ _____ 0* E q w o to L.. URUP OHIII C 0

5. 发明专利

AU2010202111A1 Compositions and methods including a recombinant human MAB that promotes CNS remyelination 未知
公开(公告)号：AU2010202111A1
公开(公告)日：2010-06-17
申请号：AU2010202111
申请日：2010-05-25
申请人： ACORDA THERAPEUTICS , MAYO FOUNDATION
发明人： RODRIGUEZ MOSES , GRUSKIN ELLIOT A , CHOJNICKI ERIC , WARRINGTON ARTHUR E , BIEBER ALLAN J
IPC分类号： A61K39/395 , A61K20060101 , A61K31/573 , C07K16/18

6. 发明专利

AU2004247021A1 Compositions and methods including a recombinant human MAB that promotes CNS remyelination 未知
公开(公告)号：AU2004247021A1
公开(公告)日：2004-12-23
申请号：AU2004247021
申请日：2004-05-17
申请人： ACORDA THERAPEUTICS , MAYO FOUNDATION FOR MEDICAL EDUCATION & RES
发明人： RODRIGUEZ MOSES , CHOJNICKI ERIC , BIEBER ALLAN J , GRUSKIN ELLIOT A , WARRINGTON ARTHUR E
IPC分类号： A61K38/00 , A61K20060101 , A61K31/573 , C07K16/18

7. 发明申请

WO2004110355A3 COMPOSITIONS AND METHODS INCLUDING A RECOMBINANT HUMAN MAB THAT PROMOTES CNS REMYELINATION 审中-公开
标题翻译：包括促进中枢神经系统重建的重组人类组合物的组合物和方法
公开(公告)号：WO2004110355A3
公开(公告)日：2006-05-18
申请号：PCT/US2004015436
申请日：2004-05-17
申请人： MAYO FOUNDATION , ACORDA THERAPEUTICS , GRUSKIN ELLIOT A , CHOJNICKI ERIC , WARRINGTON ARTHUR E , BIEBER ALLAN J , RODRIGUEZ MOSES
发明人： GRUSKIN ELLIOT A , CHOJNICKI ERIC , WARRINGTON ARTHUR E , BIEBER ALLAN J , RODRIGUEZ MOSES
IPC分类号： A61K39/395 , A61K20060101 , A61K31/573 , C07K16/18
CPC分类号： C07K16/28 , A61K31/573 , A61K39/39533 , A61K39/39541 , A61K2039/505 , A61K2039/545 , C07K16/18 , C07K2317/21 , C07K2317/56 , C07K2317/75 , A61K2300/00
摘要： Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animais, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.
摘要翻译：公开了抗体，特别是人抗体，其表现出治疗脱髓鞘疾病以及中枢神经系统的病毒，细菌或特发性起源的其它疾病，包括由脊髓损伤引起的神经功能障碍的活性。阐述神经调节剂，其包括并且包含选自能够结合中枢神经系统结构或细胞的抗体，肽类似物，半抗原，其活性片段，其激动剂，其模拟物，其单体及其组合。描述了使用多克隆IgM抗体和人单克隆抗体sHIgm22（LYM22），sHIgm46（LYM46）ebvHIgM MSI19D10，CB2bG8，AKJR4，CB2iE12，CB2iE7等治疗脱髓鞘疾病和人类和家养动物的中枢神经系统疾病的方法， MSI19E5和MSI10E10，其活性片段等。本发明还延伸到人抗体，片段，肽衍生物和类似材料及其在上述治疗应用中的用途以及含有它们的药物组合物的使用，其可以以期望的低剂量施用以治疗涉及脱髓鞘的病症，并且促进髓鞘再生。

8. 发明公开

EP1648427A4 COMPOSITIONS AND METHODS INCLUDING A RECOMBINANT HUMAN MAB THAT PROMOTES CNS REMYELINATION 有权转让
标题翻译：组合物和方法用重组人mAb促进CNS髓鞘再生
公开(公告)号：EP1648427A4
公开(公告)日：2007-04-11
申请号：EP04752450
申请日：2004-05-17
申请人： MAYO FOUNDATION , ACORDA THERAPEUTICS
发明人： GRUSKIN ELLIOT A , CHOJNICKI ERIC , WARRINGTON ARTHUR E , BIEBER ALLAN J , RODRIGUEZ MOSES
IPC分类号： C07K16/18 , A61K20060101 , A61K31/573
CPC分类号： C07K16/28 , A61K31/573 , A61K39/39533 , A61K39/39541 , A61K2039/505 , A61K2039/545 , C07K16/18 , C07K2317/21 , C07K2317/56 , C07K2317/75 , A61K2300/00
摘要： Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.

9. 发明专利

CA2967294A1 COMPOSITIONS AND METHODS INCLUDING A RECOMBINANT HUMAN MAB THAT PROMOTES CNS REMYELINATION 未知
公开(公告)号：CA2967294A1
公开(公告)日：2004-12-23
申请号：CA2967294
申请日：2004-05-17
申请人： MAYO FOUND FOR MEDICAL EDUCATION & RES , ACORDA THERAPEUTICS INC
发明人： GRUSKIN ELLIOT A , CHOJNICKI ERIC , WARRINGTON ARTHUR E , BIEBER ALLAN J , RODRIGUEZ MOSES
IPC分类号： A61K51/10 , A61K20060101 , A61K31/573 , A61K49/16 , C07K16/18

10. 发明专利

ES2366333T3 PROTEINA QUIMERICA. 未知
公开(公告)号：ES2366333T3
公开(公告)日：2011-10-19
申请号：ES03788682
申请日：2003-08-14
申请人： ACORDA THERAPEUTICS INC
发明人： GRUSKIN ELLIOTT , GARGI ROY , CHOJNICKI ERIC
IPC分类号： C12P21/06 , A61K38/00 , C12N9/88 , C12N15/62
摘要： Una proteína quimérica que comprende: 1) un primer polipéptido que posee actividad de modificación de la matriz por separación de componentes de la matriz extracelular que inhiben el crecimiento y desarrollo neuronal y que se selecciona de enzimas de digestión de la matriz; y 2) un segundo polipéptido que posee actividad de factor neurotrófico para células neurales, no presentándose conjuntamente en la naturaleza dicho primer y segundo polipéptido y estando unidos conjuntamente en dicha proteína quimérica.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式